Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates.

Bartlett EJ, Cruz AM, Esker J, Castaño A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC.

J Virol. 2008 Sep;82(18):8965-77. doi: 10.1128/JVI.00853-08. Epub 2008 Jul 9.

2.

Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.

Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL, Murphy BR, Schaap-Nutt A.

Vaccine. 2007 Aug 21;25(34):6409-22. Epub 2007 Jul 3.

3.
4.

An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials.

Surman SR, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol Methods. 2007 Apr;141(1):30-3. Epub 2007 Jan 8.

PMID:
17210187
5.

Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.

Van Cleve W, Amaro-Carambot E, Surman SR, Bekisz J, Collins PL, Zoon KC, Murphy BR, Skiadopoulos MH, Bartlett EJ.

Virology. 2006 Aug 15;352(1):61-73. Epub 2006 Jun 5.

6.

Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.

Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2006 Mar 24;24(14):2674-84. Epub 2005 Nov 15.

PMID:
16364511
7.

Individual contributions of the human metapneumovirus F, G, and SH surface glycoproteins to the induction of neutralizing antibodies and protective immunity.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR.

Virology. 2006 Feb 20;345(2):492-501. Epub 2005 Nov 21.

8.
9.

Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.

Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH.

Vaccine. 2005 Sep 7;23(38):4631-46.

PMID:
15951066
10.

The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Skiadopoulos MH, Biacchesi S, Buchholz UJ, Riggs JM, Surman SR, Amaro-Carambot E, McAuliffe JM, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2004 Jul;78(13):6927-37.

12.

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Newman JT, Riggs JM, Surman SR, McAuliffe JM, Mulaikal TA, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2004 Feb;78(4):2017-28.

13.

Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic.

Skiadopoulos MH, Schmidt AC, Riggs JM, Surman SR, Elkins WR, St Claire M, Collins PL, Murphy BR.

J Virol. 2003 Jan;77(2):1141-8.

15.

Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.

Skiadopoulos MH, Surman SR, Riggs JM, Elkins WR, St Claire M, Nishio M, Garcin D, Kolakofsky D, Collins PL, Murphy BR.

Virology. 2002 May 25;297(1):153-60.

16.

Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins.

Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR.

Virology. 2002 May 25;297(1):136-52.

17.

Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Newman JT, Surman SR, Riggs JM, Hansen CT, Collins PL, Murphy BR, Skiadopoulos MH.

Virus Genes. 2002;24(1):77-92. Erratum in: Virus Genes. 2003 Jan;26(1):107.

PMID:
11928991
18.

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.

Skiadopoulos MH, Tatem JM, Surman SR, Mitcho Y, Wu SL, Elkins WR, Murphy BR.

Vaccine. 2002 Mar 15;20(13-14):1846-52.

PMID:
11906774
19.
20.

Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone.

Tao T, Skiadopoulos MH, Davoodi F, Surman SR, Collins PL, Murphy BR.

Vaccine. 2001 Jun 14;19(27):3620-31.

PMID:
11395195
21.

Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates.

Schmidt AC, McAuliffe JM, Huang A, Surman SR, Bailly JE, Elkins WR, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2000 Oct;74(19):8922-9.

22.
23.
24.
25.
26.

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.

Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DL, Burke DS.

AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1319-28.

PMID:
8891111

Supplemental Content

Loading ...
Support Center